<DOC>
	<DOC>NCT00667810</DOC>
	<brief_summary>This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination (MMSE) score of 1626, and brain magnetic resonance imaging (MRI) consistent with the diagnosis of AD Concurrent use of cholinesterase inhibitor or memantine allowed, if stable Caregiver will participate and be able to attend clinic visits with patient Significant neurological disease other than AD Major psychiatric disorder Contraindication to undergo brain MRI [e.g., pacemaker, cerebrospinal fluid (CSF) shunt, or foreign metal objects in the body] Women of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>